Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
75 hedge funds and large institutions have $72.9M invested in Marinus Pharmaceuticals, Inc in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 28 reducing their positions, and 25 closing their positions.
176% more call options, than puts
Call options by funds: $398K | Put options by funds: $144K
44% more capital invested
Capital invested by funds: $50.6M → $72.9M (+$22.2M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 90 → 75 (-15)
29% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 28
60% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$2.2M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$1.75M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$1.7M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.14M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$600K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$3.79M |
| 2 |
LPC
Lion Point Capital
New York
|
-$1.98M |
| 3 |
Jennison Associates
New York
|
-$1.72M |
| 4 |
Goldman Sachs
New York
|
-$757K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$597K |
MRNS Hedge Fund Activity: Q3 2024 in Review
75 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q3 2024, worth a combined $72.9M — up 44% from $50.6M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of MRNS and 10 opened new positions — a net loss of 15 holders — while 28 trimmed existing stakes and 20 added.
The largest buyer was Aberdeen Group, adding an estimated $2.2M. The largest seller was Woodline Partners, cutting an estimated $3.79M.
- 75 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q3 2024, down from 90 in Q2 2024.
- Funds reported $72.9M of Marinus Pharmaceuticals, Inc stock for Q3 2024, up 44% quarter-over-quarter.
- 10 funds opened new Marinus Pharmaceuticals, Inc positions in Q3 2024 and 25 closed out, a net change of -15 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q3 2024 was Aberdeen Group, an estimated $2.2M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q3 2024 was Woodline Partners, an estimated $3.79M sold.
Based on aggregated 13F filings for Q3 2024.